US 12,404,312 B2
Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration
Yin Shan Eric Ng, North Billerica, MA (US); and Junhui Shen, Hangzhou (CN)
Assigned to Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Appl. No. 16/978,177
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US)
PCT Filed Mar. 5, 2019, PCT No. PCT/US2019/020744
§ 371(c)(1), (2) Date Sep. 3, 2020,
PCT Pub. No. WO2019/173334, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/638,775, filed on Mar. 5, 2018.
Prior Publication US 2021/0040167 A1, Feb. 11, 2021
Int. Cl. C12P 21/08 (2006.01); C07K 7/06 (2006.01); C07K 14/475 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/475 (2013.01) [C07K 7/06 (2013.01); C12N 15/86 (2013.01); C07K 2319/02 (2013.01); C07K 2319/912 (2013.01); C12N 2710/10041 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An engineered vascular endothelial growth factor (VEGF) chimeric polypeptide comprising: a first VEGF polypeptide covalently linked to a second VEGF polypeptide via a first polypeptide linker comprising the amino acid sequence of SEQ ID NO: 14, and a second polypeptide linker comprising the amino acid sequence of SEQ ID NO: 15 linking the second VEGF polypeptide to a flexible transmembrane anchor.